Stifel cuts Foghorn Therapeutics stock price target on pipeline shift
Stifel reduced Foghorn Therapeutics' (FHTX) price target to $5.00 from $12.00, citing pipeline shifts. FHTX shares trade at $2.70, down 34% YTD. The company will focus on its wholly owned pipeline, extending cash runway to mid-2029. Stifel values FHTX at $138M net cash by 2026. Citizens reiterated a Market Outperform rating with a $9.00 target.
How this was made
The 30-second read
Why it matters
The analyst downgrade reduces valuation expectations and may prompt short‑term selling, though the company retains cash and a strong balance sheet.
Market read
Target cut reflects a material change in the company's pipeline, affecting valuation and investor sentiment for this micro‑cap biotech.
What to watch
Potential partnership opportunities or licensing deals for the abandoned SMARCA2 assets.
Background
Stifel lowered its price target for Foghorn Therapeutics after the firm announced it would not advance its SMARCA2 inhibitor and degrader programs, focusing on wholly owned projects.
Ticker impact
Stifel cut its price target for Foghorn Therapeutics to $5.00 after the company halted development of its SMARCA2 programs.
likely downward pressure as investors price in the reduced target
The target cut reflects a material pipeline shift and a 40% YTD share decline, suggesting weaker upside potential.
Market effects
Biotech sector may see modest re‑rating of early‑stage pipeline companies.
US biotech investors may adjust exposure to small‑cap therapeutic firms.
Limited; impact confined to niche biotech investors.
Counterpoint
The pipeline shift could free cash for higher‑impact programs, offering upside if later milestones succeed.
Key entities
- companyFoghorn Therapeutics
Biotech firm developing epigenetic therapies, ticker FHTX.
- analystStifel
Equity research firm that cut the price target.